Neubauer, A

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 6.

Hehlmann, R; Lauseker, M; Saußele, S; Pfirrmann, M; Krause, S; Kolb, H J; Neubauer, A; Hossfeld, D K; Nerl, C; Gratwohl, A; Baerlocher, Gabriela M.; Heim, D; Brümmendorf, T H; Fabarius, A; Haferlach, C; Schlegelberger, B; Müller, M C; Jeromin, S; Proetel, U; Kohlbrenner, K; ... (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31(11), pp. 2398-2406. Nature Publishing Group 10.1038/leu.2017.253

Metzelder, S K; Schroeder, T; Lübbert, M; Ditschkowski, M; Götze, K; Scholl, S; Meyer, R G; Dreger, P; Basara, N; Fey, Martin; Salih, H R; Finck, A; Pabst, Thomas; Giagounidis, A; Kobbe, G; Wollmer, E; Finke, J; Neubauer, A; Burchert, A (2017). Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. European journal of cancer, 86, pp. 233-239. Elsevier 10.1016/j.ejca.2017.09.016

Kalmanti, L; Saussele, S; Lauseker, M; Müller, M C; Dietz, C T; Heinrich, L; Hanfstein, B; Proetel, U; Fabarius, A; Krause, S W; Rinaldetti, S; Dengler, J; Falge, C; Oppliger Leibundgut, Elisabeth; Burchert, A; Neubauer, A; Kanz, L; Stegelmann, F; Pfreundschuh, M; Spiekermann, K; ... (2015). Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia, 29(5), pp. 1123-1132. Nature Publishing Group 10.1038/leu.2015.36

Hanfstein, B; Shlyakhto, V; Lauseker, M; Hehlmann, R; Saussele, S; Dietz, C; Erben, P; Fabarius, A; Proetel, U; Schnittger, S; Krause, S W; Schubert, J; Einsele, H; Hänel, M; Dengler, J; Falge, C; Kanz, L; Neubauer, A; Kneba, M; Stegelmann, F; ... (2014). Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia, 28(10), pp. 1988-1992. Nature Publishing Group 10.1038/leu.2014.153

Metzelder, S K; Schroeder, T; Finck, A; Scholl, S; Fey, M; Götze, K; Linn, Y C; Kröger, M; Reiter, A; Salih, H R; Heinicke, T; Stuhlmann, R; Müller, L; Giagounidis, A; Meyer, R G; Brugger, W; Vöhringer, M; Dreger, P; Mori, M; Basara, N; ... (2012). High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia, 26(11), pp. 2353-2359. Basingstoke: Nature Publishing Group 10.1038/leu.2012.105

Hanfstein, B; Müller, M C; Hehlmann, R; Erben, P; Lauseker, M; Fabarius, A; Schnittger, S; Haferlach, C; Göhring, G; Proetel, U; Kolb, H-J; Krause, S W; Hofmann, W-K; Schubert, J; Einsele, H; Dengler, J; Hänel, M; Falge, C; Kanz, L; Neubauer, A; ... (2012). Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26(9), pp. 2096-102. Basingstoke: Nature Publishing Group 10.1038/leu.2012.85

This list was generated on Wed Sep 22 04:54:14 2021 CEST.
Provide Feedback